Evidence map›Paper›PMID 36213161›Full record

ArticlePathology oncology research : POR2022

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.

Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Ferenc TakácsDepartment of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Semmelweis University, Budapest, Hungary.
Lili KotmayerDepartment of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Semmelweis University, Budapest, Hungary.
Ágnes CzetiDepartment of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Semmelweis University, Budapest, Hungary.
Gábor SzalókiDepartment of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Semmelweis University, Budapest, Hungary.
Tamás LászlóDepartment of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Semmelweis University, Budapest, Hungary.
Gábor MikalaSouth-Pest Central Hospital-National Institute for Hematology and Infectious Diseases, Budapest, Hungary.
Ágnes MárkDepartment of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Semmelweis University, Budapest, Hungary.
András MassziDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
Péter FarkasDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
Márk PlanderDepartment of Hematology, Markusovszky University Teaching Hospital, Szombathely, Hungary.
Júlia WeisingerDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
Judit DemeterDepartment of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Sándor FeketeSouth-Pest Central Hospital-National Institute for Hematology and Infectious Diseases, Budapest, Hungary.
László SzerafinHospitals of Szabolcs-Szatmár-Bereg County and University Teaching Hospital, Nyíregyháza, Hungary.
Beáta Margit DeákNational Institute of Oncology, Budapest, Hungary.
Erika SzaleczkyNational Institute of Oncology, Budapest, Hungary.
Adrienn Sulák2nd Department of Internal Medicine and Cardiology Center, University of Szeged, Szeged, Hungary.
Zita Borbényi2nd Department of Internal Medicine and Cardiology Center, University of Szeged, Szeged, Hungary.
Gábor BarnaDepartment of Pathology and Experimental Cancer Research, HCEMM-SE Molecular Oncohematology Research Group, Semmelweis University, Budapest, Hungary.
HUN-REN Institute of Experimental Medicine · HUNational Institute of Oncology · HUSemmelweis University · HUNational Center for Epidemiology · HUUniversity of Szeged · HUMarkusovszky Egyetemi Oktatókórház · HUNational Healthcare Service Center · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAdenineAgammaglobulinaemia Tyrosine KinaseDrug Resistance, NeoplasmFlow CytometryHumansPiperidinesProspective StudiesProtein Kinase InhibitorsPyrazolesPyrimidinesAdenineAgammaglobulinaemia Tyrosine KinaseibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidineschronic lymphocytic leukaemiadrug resistanceflow cytometryibrutinibtargeted therapy

Identifiers

PMID36213161
PMCPMC9532522
OpenAlexW4296740218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.